News Focus
News Focus
Followers 305
Posts 37139
Boards Moderated 1
Alias Born 11/14/2013

Re: Investor082 post# 802219

Wednesday, 12/10/2025 6:10:57 PM

Wednesday, December 10, 2025 6:10:57 PM

Post# of 818487
You asked:

“Otherwise why wouldn’t a company struggling to raise cash and survive submit evidence by now.”



Here are four major reimbursement advantages that amazingly converged over the past month to strengthen reimbursement chances/amount for a therapy like DCVax-l that submits evidence to NICE around this month instead of earlier.

1. QALY threshold officially raised, effective date April 2026.
(Announced around December 1, 2025)

2. Ten year data from last randomization reached.
(November 6, 2025)

3. UK will substantially reduce clawback tax to innovative drug corporations, thus making it cheaper for them to do business in the UK. (Announced Today, December 10, 2025)

4. Tariffs removed by USA on therapy exports to U.S. from the UK.
(Announced Today, December 10, 2025)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News